However, a recent study by Kawazoe and colleagues33 reported an association between PD-L1 expression and clinicopathological parameters (TCs: mismatch repair deficient, PIK3CA mutation, and KRAS mutation; immune cells: EBV positivity and lymph node metastasis) using the IHC 22C3 pharmDx kit in metastatic GC, but IC and TC were scored separately in the study. Here, KRAS is linked to metastatic malignant neoplasm in the lymph nodes.